JP2022521801A5 - - Google Patents

Info

Publication number
JP2022521801A5
JP2022521801A5 JP2021550168A JP2021550168A JP2022521801A5 JP 2022521801 A5 JP2022521801 A5 JP 2022521801A5 JP 2021550168 A JP2021550168 A JP 2021550168A JP 2021550168 A JP2021550168 A JP 2021550168A JP 2022521801 A5 JP2022521801 A5 JP 2022521801A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fluoro
effective amount
benzo
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021550168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019884 external-priority patent/WO2020176610A1/en
Publication of JP2022521801A publication Critical patent/JP2022521801A/ja
Publication of JP2022521801A5 publication Critical patent/JP2022521801A5/ja
Pending legal-status Critical Current

Links

JP2021550168A 2019-02-28 2020-02-26 多発性骨髄腫を治療するための方法 Pending JP2022521801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812002P 2019-02-28 2019-02-28
US62/812,002 2019-02-28
PCT/US2020/019884 WO2020176610A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Publications (2)

Publication Number Publication Date
JP2022521801A JP2022521801A (ja) 2022-04-12
JP2022521801A5 true JP2022521801A5 (https=) 2023-03-02

Family

ID=72238680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550168A Pending JP2022521801A (ja) 2019-02-28 2020-02-26 多発性骨髄腫を治療するための方法

Country Status (11)

Country Link
US (1) US20220143016A1 (https=)
EP (1) EP3931196A4 (https=)
JP (1) JP2022521801A (https=)
CN (1) CN113710670A (https=)
AU (1) AU2020227748A1 (https=)
BR (1) BR112021016747A2 (https=)
CA (1) CA3131249A1 (https=)
EA (1) EA202192117A1 (https=)
IL (1) IL285800A (https=)
MX (1) MX2021010398A (https=)
WO (1) WO2020176610A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (https=) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
EP2624818B1 (en) * 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EA034866B1 (ru) * 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
EP3836932A2 (en) * 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Similar Documents

Publication Publication Date Title
JP2017531038A5 (https=)
JP2024516371A5 (https=)
JP6364546B2 (ja) 抗腫瘍剤の副作用軽減剤
JP2016518437A5 (https=)
JP2020504733A5 (https=)
JP2020512337A5 (https=)
WO2006010574A1 (en) Piperazine derivatives for the treatment of female sexual disorders
JP2017518334A5 (https=)
JP2008505902A5 (https=)
JP2013507415A5 (https=)
JP2020507589A5 (https=)
JP2005506308A5 (https=)
JP2020097577A5 (https=)
CN115315423A (zh) 取代芳基类化合物
JP2019527724A5 (https=)
JP2015521156A5 (https=)
JP2010521516A5 (https=)
JP2020518629A5 (https=)
JP2009532438A5 (https=)
JP2018522927A5 (https=)
JP2004525183A5 (https=)
JP2023550902A5 (https=)
JP2021530440A5 (https=)
JP2022521801A5 (https=)
JP2022509763A5 (https=)